Shedding Light on Mechanisms of Myocarditis With COVID-19 mRNA Vaccines

HomeCirculationVol. 147, No. 11Shedding Light on Mechanisms of Myocarditis With COVID-19 mRNA Vaccines No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextShedding Light on Mechanisms of Myocarditis With COVID-19 mRNA Vaccines Biykem Bozkurt Biykem BozkurtBiykem Bozkurt Correspondence to: Biykem Bozkurt, MD, PhD, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030. Email E-mail Address: [email protected] https://orcid.org/0000-0002-6362-0253 Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, DeBakey VA Medical Center, Houston TX. Search for more papers by this author Originally published16 Feb 2023https://doi.org/10.1161/CIRCULATIONAHA.123.063396Circulation. 2023;147:877–880This article is a commentary on the followingCirculating Spike Protein Detected in Post–COVID-19 mRNA Vaccine MyocarditisFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 880.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Biykem Bozkurt, MD, PhD, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030. Email [email protected]eduReferences1. Ling RR, Ramanathan K, Tan FL, Tai BC, Somani J, Fisher D, MacLaren G. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis.Lancet Respir Med. 2022; 10:679–688. doi: 10.1016/S2213-2600(22)00059-5CrossrefMedlineGoogle Scholar2. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines.Circulation. 2021; 144:471–484. doi: 10.1161/CIRCULATIONAHA.121.056135LinkGoogle Scholar3. Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, Scorilas A, Kastritis E, Andreakos E, Dimopoulos MA. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis.Trends Mol Med. 2022; 28:542–554. doi: 10.1016/j.molmed.2022.04.007CrossrefMedlineGoogle Scholar4. Yonker LM, Swank Z, Bartsch YC, Burns MD, Kane A, Boribong BP, Davis JP, Loiselle M, Novak T, Senussi Y, et al. Circulating spike protein detected in post-COVID-19 mRNA vaccine myocarditis.Circulation. 2023; 147:867–876. doi: 10.1161/CIRCULATIONAHA.122.061025LinkGoogle Scholar5. Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how.Int J Biol Sci. 2021; 17:1446–1460. doi: 10.7150/ijbs.59233CrossrefMedlineGoogle Scholar6. Ogata AF, Cheng CA, Desjardins M, Senussi Y, Sherman AC, Powell M, Novack L, Von S, Li X, Baden LR, et al. Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients.Clin Infect Dis. 2022; 74:715–718. doi: 10.1093/cid/ciab465CrossrefMedlineGoogle Scholar7. Fertig TE, Chitoiu L, Marta DS, Ionescu VS, Cismasiu VB, Radu E, Angheluta G, Dobre M, Serbanescu A, Hinescu ME, et al. Vaccine mRNA can be detected in blood at 15 days post-vaccination.Biomedicines. 2022; 10:1538. doi: 10.3390/biomedicines10071538CrossrefMedlineGoogle Scholar8. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, Olson SM, Talbot HK, Casey JD, Mohr NM, et al; IVY Network. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021.MMWR Morb Mortal Wkly Rep. 2021; 70:1337–1343. doi: 10.15585/mmwr.mm7038e1CrossrefMedlineGoogle Scholar9. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.Nat Med. 2022; 28:410–422. doi: 10.1038/s41591-021-01630-0CrossrefMedlineGoogle Scholar10. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC, et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex.Circulation. 2022; 146:743–754. doi: 10.1161/CIRCULATIONAHA.122.059970LinkGoogle Scholar11. Li C, Chen Y, Zhao Y, Lung DC, Ye Z, Song W, Liu F-F, Cai J-P, Wong W-M, Yip CC, et al. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in mouse model.Clin Infect Dis. 2022; 74:1933–1950. doi: 10.1093/cid/ciab707CrossrefMedlineGoogle Scholar12. Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action.NPJ Vaccines. 2021; 6:104. doi: 10.1038/s41541-021-00369-6CrossrefMedlineGoogle Scholar13. Murphy WJ, Longo DL. A possible role for anti-idiotype antibodies in SARS-CoV-2 infection and vaccination.N Engl J Med. 2022; 386:394–396. doi: 10.1056/NEJMcibr2113694CrossrefMedlineGoogle Scholar14. Avolio E, Carrabba M, Milligan R, Kavanagh Williamson M, Beltrami AP, Gupta K, Elvers KT, Gamez M, Foster RR, Gillespie K, et al. The SARS-CoV-2 spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease.Clin Sci (Lond). 2021; 135:2667–2689. doi: 10.1042/CS20210735CrossrefMedlineGoogle Scholar15. Lei Y, Zhang J, Schiavon CR, He M, Chen L, Shen H, Zhang Y, Yin Q, Cho Y, Andrade L, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2.Circ Res. 2021; 128:1323–1326. doi: 10.1161/CIRCRESAHA.121.318902LinkGoogle Scholar16. Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.Clin Immunol. 2020; 217:108480. doi: 10.1016/j.clim.2020.108480CrossrefMedlineGoogle Scholar17. Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine.Immunol Res. 2020; 68:310–313. doi: 10.1007/s12026-020-09152-6CrossrefMedlineGoogle Scholar18. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting.N Engl J Med. 2021; 385:1078–1090. doi: 10.1056/NEJMoa2110475CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesCirculating Spike Protein Detected in Post–COVID-19 mRNA Vaccine MyocarditisLael M. Yonker, et al. Circulation. 2023;147:867-876 March 14, 2023Vol 147, Issue 11 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.063396PMID: 36794591 Originally publishedFebruary 16, 2023 KeywordsSARS-COV-2mRNA vaccinesvaccineEditorialsmyocarditisCOVID-19PDF download Advertisement SubjectsCardiotoxicityInflammatory Heart Disease